Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H16FN2O14P3 |
Molecular Weight | 500.1587 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CN([C@H]2O[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@H](O)[C@H]2F)C(=O)NC1=O
InChI
InChIKey=RUKRVHYQIIURNV-XQXXSGGOSA-N
InChI=1S/C10H16FN2O14P3/c1-4-2-13(10(16)12-8(4)15)9-6(11)7(14)5(25-9)3-24-29(20,21)27-30(22,23)26-28(17,18)19/h2,5-7,9,14H,3H2,1H3,(H,20,21)(H,22,23)(H,12,15,16)(H2,17,18,19)/t5-,6+,7-,9-/m0/s1
Molecular Formula | C10H16FN2O14P3 |
Molecular Weight | 500.1587 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:12:04 UTC 2023
by
admin
on
Sat Dec 16 08:12:04 UTC 2023
|
Record UNII |
GYY7PAS72J
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
174625-00-4
Created by
admin on Sat Dec 16 08:12:04 UTC 2023 , Edited by admin on Sat Dec 16 08:12:04 UTC 2023
|
PRIMARY | |||
|
m3621
Created by
admin on Sat Dec 16 08:12:04 UTC 2023 , Edited by admin on Sat Dec 16 08:12:04 UTC 2023
|
PRIMARY | Merck Index | ||
|
503024
Created by
admin on Sat Dec 16 08:12:04 UTC 2023 , Edited by admin on Sat Dec 16 08:12:04 UTC 2023
|
PRIMARY | |||
|
GYY7PAS72J
Created by
admin on Sat Dec 16 08:12:04 UTC 2023 , Edited by admin on Sat Dec 16 08:12:04 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|